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Abstract: Many people consume coffee to attenuate increased sleepiness and impaired vigilance and
attention due to insufficient sleep. We investigated in genetically caffeine sensitive individuals whether
‘real world’ coffee consumption during a simulated busy work week counteracts disabling consequences
of chronically restricted sleep. We subjected homozygous C-allele carriers of ADORA2A (gene encoding
adenosine A2A receptors) to 5 nights of only 5 h time-in-bed. We administered regular coffee (n = 12;
200 mg caffeine at breakfast and 100 mg caffeine after lunch) and decaffeinated coffee (n = 14) in double-
blind fashion on all days following sleep restriction. At regular intervals 4 times each day, participants
rated their sleepiness and performed the psychomotor vigilance test, the visual search task, and the visuo-
spatial and letter n-back tasks. At bedtime, we quantified caffeine and the major caffeine metabolites
paraxanthine, theobromine and theophylline in saliva. The 2 groups did not differ in age, body-mass-
index, sex-ratio, chronotype and mood states. Subjective sleepiness increased in both groups across
consecutive sleep restriction days and did not differ. By contrast, regular coffee counteracted the impact
of repeated sleep loss on sustained and selective attention, as well as executive control when compared
to decaffeinated coffee. The coffee induced benefits on different aspects of performance lasted for 4–5
days of insufficient sleep. All differences between the groups disappeared after the recovery night and the
cessation of coffee administration. The data suggest that ‘real world’ coffee consumption can efficiently
attenuate sleep restriction-induced impairments in vigilance and attention in genetically caffeine sensitive
individuals.
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A B S T R A C T   
Many people consume coffee to attenuate increased sleepiness and impaired vigilance and attention due to 
insufficient sleep. We investigated in genetically caffeine sensitive men and women whether ‘real world’ coffee 
consumption during a simulated busy work week counteracts disabling consequences of chronically restricted 
sleep. We subjected homozygous C-allele carriers of ADORA2A (gene encoding adenosine A2A receptors) to five 
nights of only 5 h time-in-bed. We administered regular coffee (n = 12; 200 mg caffeine at breakfast and 100 mg 
caffeine after lunch) and decaffeinated coffee (n = 14) in double-blind fashion on all days following sleep re-
striction. At regular intervals four times each day, participants rated their sleepiness and performed the psy-
chomotor vigilance test, the visual search task, and the visuo-spatial and letter n-back tasks. At bedtime, we 
quantified caffeine and the major caffeine metabolites paraxanthine, theobromine and theophylline in saliva. The 
two groups did not differ in age, body-mass-index, sex-ratio, chronotype and mood states. Subjective sleepiness 
increased in both groups across consecutive sleep restriction days and did not differ. By contrast, regular coffee 
counteracted the impact of repeated sleep loss on sustained and selective attention, as well as executive control 
when compared to decaffeinated coffee. The coffee also induced initial or transient benefits on different aspects 
of baseline performance during insufficient sleep. All differences between the groups disappeared after the re-
covery night and the cessation of coffee administration. The data suggest that ‘real world’ coffee consumption 
can efficiently attenuate sleep restriction-induced impairments in vigilance and attention in genetically caffeine 
sensitive individuals. 
German Clinical Trial Registry: # DRSK00014379.   
1. Introduction 
Undisturbed sleep of sufficient duration is a prerequisite for personal 
well-being and health and is essential for alertness and cognitive per-
formance necessary for safe and effective functioning. Despite this 
knowledge, representative national surveys indicate that more than 30% 
of the adult population in Western societies report sleeping less than the 
commonly recommended 7–8 h on weekday nights, and roughly 15% 
regularly sleep less than 6 h (Basner et al., 2014; Tinguely et al., 2014). 
Consistent with the prevalent co-occurrence of insufficient sleep and 
excessive daytime sleepiness (Ohayon, 2008), increased sleepiness 
belongs to the first signs of experimentally induced insufficient sleep (Lo 
et al., 2012). 
Similarly, a general slowing in response speed and an increased 
number of attentional lapses on a psychomotor vigilance test (PVT) is 
typically observed in normal sleepers when time-in-bed is restricted to 
5–6 h over several nights (Van Dongen et al., 2003; Balkin et al., 2004; 
Lo et al., 2012). These findings corroborate the notion that simple, 
reaction-time based tasks of vigilance such as the PVT are very sensitive 
to insufficient sleep (Tkachenko and Dinges, 2018). By contrast, more 
demanding waking functions such as working memory and response 
inhibition, which also rely on underlying aspects of attention, appear to 
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be less affected. 
A currently prevailing model posits that three separate but inter-
acting attentional networks regulate vigilance (alerting network), ori-
enting (orienting and selection network), and executive attention 
(executive control network) (Petersen and Posner, 2012). These net-
works respond in concert to environmental stimuli but are largely in-
dependent (Fan et al., 2005). It is assumed that the alerting network 
prepares and maintains responses to salient stimuli, the orienting 
network isolates desired stimuli for processing and directs attention to a 
target stimulus, and the executive control network allocates attentional 
resources to manage cognitive workload (Petersen and Posner, 2012). 
Sleep deprivation, as well as acute and chronic sleep restriction impair 
not only vigilance but also executive control, albeit with a lower effect 
size (Lo et al., 2012). Conversely, tasks assessing orienting appear 
largely unaffected by acute sleep restriction (Cunningham et al., 2018). 
These findings suggest that insufficient sleep differently affects distinct 
attentional network systems which may provide distinct targets for 
pharmacological interventions to mitigate sleep-loss induced attentional 
impairments (Dijk and Landolt, 2019). 
To enhance wakefulness in response to sleep restriction, intake of 
caffeine is highly common, particularly in the morning and early after-
noon (Martyn et al., 2018). It is estimated that more than 80% of the 
world’s population consume caffeine on a daily basis, with coffee being 
the most common dietary source (Clark and Landolt, 2017; Martyn et al., 
2018). The average daily caffeine intake per adult equals ~300 mg in 
Europe and South America, and ~200 mg in the US (Heckman et al., 
2010; Urry et al., 2017; Frozi et al., 2018; Martyn et al., 2018). By 
blocking A1 and A2A receptors of the sleep promoting neuromodulator 
adenosine, caffeine facilitates cholinergic and monoaminergic neuro-
transmission in brain regions that regulate vigilance and higher-order 
attentional processes (Fan et al., 2005). Consistent with this mode of 
action, acute caffeine administration between ~200–300 mg preserves 
vigilance and all aspects of attention, in particular when performance 
degrading factors such as insufficient sleep are present (Jarvis, 1993; 
Lieberman et al., 2002). Nevertheless, it is currently unclear whether the 
evidence from studying acute caffeine effects can be translated to real 
world consumption, where caffeinated beverages are commonly 
consumed every day. Indeed, it was recently reported that repeated 
administration of 300–450 mg caffeine per day failed to improve vigi-
lance performance in rested and sleep restricted individuals (Bartrim 
et al., 2020; Weibel et al., 2020). Remarkably, after a short-lived initial 
benefit, sleepiness and attentional lapses were even enhanced after 
caffeine in comparison to placebo when sleep was restricted for more 
than three nights (Doty et al., 2017). In conclusion, it is currently not 
known whether daily coffee intake in a dose and timing that mimics ‘real 
world’ European habits maintains simple and complex attentional pro-
cesses during repeated sleep restriction. 
Not only dose and frequency of administration, but also pronounced 
inter-individual differences determine the subjective and objective re-
sponses to caffeine and may hamper conclusions on its potency to 
enhance vigilance and attention. These inter-individual differences are 
robust and in part genetically determined. More specifically, genetic 
variants of the adenosine A2A receptor gene (ADORA2A), in particular 
the c.1976T>C variant, were consistently found to modulate neuro-
behavioral performance during sleep restriction (Bodenmann et al., 
2012; Rupp et al., 2013), as well as individual effects of caffeine on self- 
reported alertness (Rogers et al., 2010), attention network functions 
(Renda et al., 2015; Geiger et al., 2016) and sleep (Rétey et al., 2007; 
Bodenmann et al., 2012). These findings suggest that prospective gen-
otyping of the c.1976T>C variant of ADORA2A could provide clearer 
outcomes on the potential usefulness of coffee as a countermeasure 
against impaired attention due to insufficient sleep. 
To tackle this question, we subjected two carefully matched groups 
of homozygous C-allele carriers of ADORA2A to repeated sleep restric-
tion and studied the effects of standardized regular coffee (300 mg 
caffeine per day) or decaffeinated coffee (< 3 mg caffeine per day) on 
subjective sleepiness and different facets of attention. We hypothesized 
that daily coffee consumption in genetically caffeine sensitive in-
dividuals attenuates sleepiness and the impairment of performance on 
all attentional domains during a five-day simulated busy workweek of 
only 5 h time-in-bed each night. 
2. Materials and methods 
All study procedures were approved by the ethics committee of 
North Rhine (“Ärztekammer Nordrhein”), the German Federal Office for 
Radiation Protection (“Deutsches Bundesamt für Strahlenschutz”) and 
carried out in accordance with the Declaration of Helsinki. All partici-
pants gave written informed consent before participating in the study. 
2.1. Participants 
Prospective study participants aged between 20 and 40 years were 
recruited through the internal test subject database of the Institute of 
Aerospace Medicine of the German Aerospace Center (Deutsches Zen-
trum für Luft- und Raumfahrt e.V.; DLR), as well as advertisements on 
public websites. Individuals interested in study participation were pro-
vided with more details via e-mail and asked to complete a dedicated 
screening questionnaire. Exclusion criteria included a reported body- 
mass-index (BMI) > 30, presence of sleep-wake disorders and any 
chronic diseases, habitual nightly sleep duration outside the range of 
6–9 h, current shift work and jet-lag, history of head injury, and alcohol 
or substance abuse. Participants were only evaluated further if they 
reported no current medication (except contraceptives) and nicotine 
intake and an estimated habitual caffeine consumption below 450 mg/ 
day. To eligible volunteers, we sent by mail a parcel containing detailed 
information and a saliva self-collection kit (DNA Genotek Inc., Ottawa, 
Canada). They were asked to provide a saliva sample for determination 
of the c.1976T>C polymorphism (SNP-ID: rs5751876) of the gene 
ADORA2A. A total of 309 OraGene-500 test-kits was genotyped. A 
detailed flow chart of participant recruitment is provided in Supple-
mentary Fig. S1. 
2.2. Determination of the c.1976T>C genotype 
According to the manufacturer’s instructions, genomic DNA was 
extracted following an ethanol precipitation protocol using prepIT re-
agent (prepIT-L2P), such as described previously (Urry et al., 2017). 
Allele-specific primers were used for selective amplification of each 
allele (forward primer specific for allele T: 5′-CGG AGG CCC AAT GGC 
TAT-3′, forward primer specific for allele C: 5′-CGG AGG CCC AAT 
GGCTAC-3′, and reverse primer: 5′-GTG ACT GGT CAAGCC AAC CA-3′). 
Fragments containing 10 ng genomic DNA were amplified using a 
TaqDNA Polymerase (Thermo Fisher Scientific, Whaltham, USA) and a 
“hot start” procedure. Specifically, an initial denaturating step (10 min, 
95 ◦C) was followed by 40 cycles of denaturation (1 min, 92 ◦C), 
annealing and elongation (1 min, 60 ◦C), using an Applied Biosystems 
GeneAmp PCR System 2700 thermal cycler (Applied Biosystems, Foster 
City, USA). An Applied Biosystems PRISM 7900HT with SDS software 
version 2.2 was used for allelic discrimination and fluorescence detec-
tion. Consistent with the expected allele frequencies of a Western Eu-
ropean study sample (Rétey et al., 2007), 105 homozygous C-allele 
carriers (34.0%) were identified. 
2.2.1. Pre-study procedures and experimental protocol 
During at least one week preceding the study, participants were 
asked to adhere to a regular sleep-wake schedule of 9 h of sleep, starting 
at 22:00/23:00, and 15 h of wakefulness. They wore a wrist activity 
monitor and completed a sleep-wake diary, to verify compliance with 
this instruction. Naps and caffeine, alcohol and medication intake were 
not permitted (occasional medication intake unknown to interfere with 
sleep or performance could be allowed upon consultation). 
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The experimental portion of the study was conducted under 
controlled conditions in a dedicated, state-of-the-art research facility of 
the Institute for Aerospace Medicine at the DLR’s headquarter in Co-
logne (https://www.dlr.de/envihab/). Upon arrival, prospective study 
participants were pseudo-randomly assigned to one of two coffee 
groups, stratified by sex, age and BMI, to either receive standardized 
regular coffee or decaffeinated coffee during chronic sleep restriction. A 
member of the medical staff informed all volunteers about the objec-
tives, as well as the risks of the study. Adherence to all pre-study in-
structions, including urine toxicological screening and saliva caffeine 
quantification, was verified. In addition, in the first night following 
arrival at the laboratory the absence of sleep-wake disturbances was 
confirmed in an adaptation/screening night. Individuals with an apnea- 
hypopnea index higher than 10 and a periodic leg movement index 
higher than 15 were excluded from study participation. 
The experimental protocol consisted of 9 consecutive days and nights 
(Fig. 1), aimed at investigating the effects of coffee intake on subjective 
state, attention, declarative memory, decision making, risk taking, sleep 
architecture, the sleep and waking EEG, as well as cerebral adenosine A1 
receptor binding in vivo before, during, and after recovery from sleep 
restriction. After the adaptation/screening and two baseline nights (BS1 
& BS2; either from 23:00–07:00 [n = 14] or from 00:00–08:00 [n = 12], 
according to each participant’s self-selected sleep-wake schedule during 
the pre-study weeks), sleep was restricted to 5 h time-in-bed during five 
consecutive days (CS1-CS5; either from 02:00–07:00 [n = 14] or from 
03:00–08:00 [n = 12]). The study was concluded with an 8-h recovery 
night (RN; either from 23:00–07:00 [n = 14] or from 00:00–08:00 [n =
12]). All measurements and recordings were scheduled at identical 
times awake. 
All participants slept in their own single bedroom, where during the 
day test sessions at the computer took place at regular time intervals. 
When not engaged in sleep or cognitive testing, participants remained in 
a common living area to read, eat, play games, or watch television and 
movies. Light intensity was set at <100 lx during waking hours to 
minimize light’s acute alerting effect and impact on circadian rhythms. 
The volunteers were not allowed to leave the research facility during the 
entire experimental period. During the study, naps, smoking, caffeine 
(except experimental coffee intake), alcohol, medications, and sports 
were not allowed. Violation of protocol instructions lead to exclusion 
from further participation in the study. 
During the pre-study procedures, at screening and in the course of 
the experiment, 42 individuals needed to be excluded (referred to as 
“late drop-outs”) (Supplementary Fig. S1). The typical reasons for 
exclusion included non-compliance to the imposed sleep-wake schedule, 
positive toxicological screening, and increased apnea-hypopnea or 
periodic-leg-movement index in the screening night. Twenty-seven ho-
mozygous rs5751876 C-allele carriers completed the study. Because one 
participant of the regular coffee group performed outside the normal 
range on virtually all cognitive tasks and her data differed by >2 stan-
dard deviations from the values of the other participants, this dataset 
was excluded from the analyses. The demographic characteristics of the 
remaining 26 individuals are summarized in Table 1. The two experi-
mental groups did not differ on any demographic criteria considered. 
2.3. Coffee preparation and administration 
Two batches of coffee and high-quality, electric drip filter coffee 
machines (Tchibo type 5794 and 2855) were obtained from the same 
manufacturer (Tchibo GmbH, Coffee Technology, Hamburg, Germany). 
The coffee was brewed according to detailed instructions provided by 
the manufacturer, whose pre-study analytics confirmed that adherence 
to the brewing instructions produced a content of 101 ± 0.6 mg (SD) 
caffeine per 200 g of regular coffee and 2.4 ± 0.05 mg caffeine per 200 g 
Fig. 1. Experimental protocol. Dark grey shading: sleep op-
portunities recorded with standard polysomnography. Adap-
tation: adaptation/screening night; BS1, BS2: baseline nights; 
CS1-5: sleep restriction nights; RN: recovery night. Yellow 
shading: monitored wakefulness under controlled laboratory 
conditions. Light grey shading: neurobehavioral test battery 
consisting of Karolinska Sleepiness Scale (KSS), psychomotor 
vigilance test (PVT), visual search task (VST), and visuo- 
spatial and letter n-back tasks. Red asterisks indicate the 
times of saliva collection for caffeine quantification. Coffee 
mugs indicate coffee administration. Red circles: high-density 
waking EEG recordings. Yellow asterisks: reversal learning 
decision task (RLDT). Yellow triangles: risk task. (For inter-
pretation of the references to colour in this figure legend, the 
reader is referred to the web version of this article.)   
Table 1 
Demographic characteristics of study participants.   




n 12 14  
Gender ratio 6 female/6 
male 
6 female/8 male  
Age (years) 29.9 ± 5.3 28.6 ± 5.4 0.42 
Chronotype (MCTQ) 04:25 ± 56 
min 
04:28 ± 51 min 0.82 
Epworth Sleepiness Scale 5.9 ± 3.1 4.9 ± 2.7 0.37 
PANAS (Positive Affect 
Schedule) 
35.2 ± 3.2 33.8 ± 10.6 0.62 
PANAS (Negative Affect 
Schedule) 
13.8 ± 2.9 13.7 ± 3.2 0.96 
Beck Depression Inventory 
(BDI-II) 
1.8 ± 2.4 1.4 ± 1.6 0.68 
Body mass index (kg/m2) 23.2 ± 3.2 23.6 ± 2.5 0.85 
Habitual caffeine intake (mg/ 
day) 
156 ± 124 113 ± 91 0.25 
Values represent means and standard deviations. All study participants were 
ADORA2A c.1976T>C homozygous C/C allele carriers. MCTQ = Munich 
ChronoType Questionnaire, values represent time of mid-sleep on free days 
corrected for sleep debt, ESS = Epworth Sleepiness Scale, PANAS = Positive and 
Negative Affect Schedule Questionnaire, Body Mass Index and habitual caffeine 
intake per day were estimated from recruitment survey, Genotype was deter-
mined by analyzing DNA from a saliva sample. P-values are derived from a two- 
tailed, unpaired t-test. 
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of decaffeinated coffee (data available on file). On all days following 
sleep restriction, 400 and 200 g regular (coded as batch “162”) or 
decaffeinated coffee (coded as batch “833”), respectively, were admin-
istered in double-blind fashion at 07:30/08:30 and 14:00/15:00. A daily 
dose of ~300 mg caffeine roughly matches the estimated habitual 
caffeine intake patterns from wastewater analyses in Zurich, 
Switzerland (Gracia-Lor et al., 2017). On sleep restriction day 5, the 
midday coffee intake was omitted to avoid interference with the 
scheduled positron emission tomography (PET) scanning (Fig. 1). All 
members of the research team were blind to the identity of the two 
coffee batches throughout data collection and statistical analyses of the 
subjective and behavioral data. 
2.4. Subjective sleepiness 
To quantify the evolution of subjective sleepiness throughout the 
experimental protocol, the Karolinska Sleepiness Scale (KSS) was 
administered before each test session devised to assess the different 
components of attention (see below). The KSS is a widely validated 9- 
point Likert scale to estimate the subjects’ self-reported momentary 
level of drowsiness/sleepiness. It ranges from “1” (extremely alert) to 
“9” (extremely sleepy, fighting sleep) (Åkerstedt and Gillberg, 1990). 
2.5. Testing attention network functions 
To study the effects of coffee intake during chronic sleep restriction 
on different functional aspects of attention, a 35-min test battery was 
administered on all experimental days at 09:00/10:00, 12:00/13:00, 
18:00/19:00, and 21:00/22:00 (Fig. 1). To examine all three attentional 
networks, each test session included validated versions of a psychomotor 
vigilance test, a visual search task, and a visuo-spatial and letter (verbal) 
n-back task. 
2.5.1. Vigilance and alerting network 
The psychomotor vigilance test (PVT) is a gold-standard measure-
ment of sustained vigilant attention in sleep and chronobiology research 
(Dinges and Powell, 1985). This test relies on measuring the reaction 
time (RT) to a digital ms-counter on a computer screen that starts to 
scroll randomly ~100 times with variable inter-stimuli intervals be-
tween 2 and 10 s over a test duration of 10 min. The RTs below 100 ms 
were defined as errors of commission and excluded, whereas the RT 
above 500 ms were defined as errors of omission (lapses) and also 
omitted from the analyses of mean RT. Speed (1/RT), the number of 
lapses, accuracy, and the log-transformed signal-to-noise ratio (LSNR) 
on the PVT were analyzed. Accuracy was defined as the sum count of 
true positives over the total number of stimuli, thus also taking into 
account lapses (RT > 500 ms) and false positive responses (RT < 100 
ms). The LSNR was previously suggested to quantify PVT performance 
with high sensitivity, stability, normal distribution, and absence of floor 
and ceiling effects (Chavali et al., 2017). This novel measure of PVT 
performance is independent of the absolute position on the metric scale 
(Chavali et al., 2017). 
The signal-to-noise-ratio (SNR) of PVT performance was approxi-


























where Si = 1/(RTi – C), wi = 1/(r2Si + 1), C = 100 ms, r 2 = 196 ms, RTi is 
the ith RT (in ms), and N is the number of trials in the PVT session. RT <
100 ms (i.e., false starts) were not included. The log-transformed form of 
this metric as LSNR = 10log10(SNR) expressed in decibel (dB) was 
analyzed. 
2.5.2. Orienting and selection network 
The visual search task probes the distinct subsystems of the attention 
network, which relate to searching and selecting stimuli for further 
processing (orienting) (Pashler, 1987). In the visual search paradigm 
employed here, the study participants were instructed to find a target 
item as fast and precisely as possible (i.e., the digit ‘2’) on a display 
cluttered with distractor items (i.e., the digit ‘5’) (Santhi et al., 2007). 
The target was either present or not present and the set size of search 
items varied between 10, 20, 30 and 40. Speed (excluding RTs < 100 ms) 
and accuracy (i.e., sum of true positives and true negatives divided by 
total amount of responses) were analyzed. 
2.5.3. Executive control network 
A visuo-spatial and a letter n-back task were employed to probe 
working memory and the executive control network responsible for the 
allocation of attentional resources (Owen et al., 2005). With increasing 
cognitive workload, these tasks require the short-term managing and 
updating of information and as such tap into the executive control of 
attention. Participants were presented with a series of dot positions and 
letters on a computer screen and asked to press a button if the current 
stimulus was presented 1, 2, or 3 steps back. Each of the 3 cognitive 
workload levels consisted of 20 targets and 40 non-targets. The data 
were analyzed for speed (including only correct answers and RTs > 100 
ms for calculating average values) and accuracy of task responses. Ac-
curacy was defined as the sum of hits and correct rejections, divided by 
the amount of total responses. 
2.6. Quantification of caffeine and caffeine metabolites in saliva 
Saliva samples for the quantification of caffeine and its main me-
tabolites, paraxanthine, theobromine, and theophylline were collected 
in Salivette® tubes (Sarstedt, Germany) on all experimental days at 
bedtime (except for RN where no coffee was administered), as well as in 
the morning of experimental days B1, B2, CS5 and RN (Fig. 1). The 
samples were stored at −20 ◦C and only quantified when the analyses of 
the subjective and behavioral data were completed. For metabolite 
quantification, internal standards (IS) had to be prepared consisting of 
caffeine, theophylline, theobromine and caffeine-13C3, purchased from 
Sigma-Aldrich (St. Louis, USA), and paraxanthine purchased from Cer-
illiant (Texas, USA). All chemicals used were of the highest grade 
available. For sample preparation, 280 μl of saliva, 70 μl of the IS (8 μM 
caffeine-13C3) and 1000 μl of ethyl acetate were added to a tube. Sam-
ples were shaken for 10 min and centrifuged (5 min, 10′000 rpm). 800 μl 
of the supernatant was transferred into an auto-sampler vial and evap-
orated to dryness under a gentle stream of nitrogen and reconstituted in 
250 μl of an eluent-mixture (95:5, v/v). Calibrator (Cal) and quality 
control (QC) samples were prepared with the same sample preparation, 
but 70 μl of the Cal or QC solutions were added before adding 930 μl of 
ethyl acetate. The saliva samples were analyzed using an ultra-high- 
performance liquid chromatography (UHPLC) system (Thermo Fisher, 
San Jose, CA), coupled to a linear ion trap quadrupole mass spectrom-
eter 5500 (Sciex, Darmstadt, Germany). The mobile phases of the 
UHPLC consisted of water (eluent A) and a mixture (70:30 v/v) of 
methanol and acetonitrile (eluent B), both containing 0.1% of formic 
acid (v/v). The flow rate was set to 0.45 ml/min with the following 
gradient: start conditions 95% of eluent A, decreasing in 3 min to 80%, 
and a quick decrease to 2% A within 0.5 min, holding these conditions 
for 1 min and then switch to the starting conditions for a 1 min re- 
equilibration. Injection volume was 5 μl. A Kinetex Biphenyl column 
(50 × 2.1 mm, 1.7 μm) (Phenomenex, Aschaffenburg, Germany) was 
used for the separation of the analytes. Mass spectrometer (MS) was 
operated in positive electrospray ionization mode with scheduled mul-
tiple reaction monitoring (MRM) (Kondrat et al., 1978) with a detection 
window of 35 s and a target scan time of 1.1 s. Three MRM transitions 
were used for each analyte. For analyte quantification, peak areas were 
integrated and divided by the peak area of the IS. Cal samples were fitted 
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with a least-squares fit and weighted by 1/x. 
The caffeine and metabolite concentrations in the final five study 
participants (two members of the regular coffee group and three mem-
bers of the decaffeinated coffee group) could not be analyzed because 
the UHPLC/MS system was not available. The results of the pharmaco-
kinetic analyses thus rely on ten volunteers who received regular coffee 
and eleven volunteers who received decaffeinated coffee. 
2.7. Data analyses 
In this manuscript, we report the effects of common coffee intake on 
subjective sleepiness and the distinct components of attention (vigi-
lance, orienting and executive control) during chronic sleep restriction. 
All analyses were conducted using R version 4.0.0 (R Core Team, 2018) 
and RStudio Version 1.2.5042 (RStudio, Inc.). Data were analyzed via 
linear mixed effects models (R package lme4 v.1.1.23 and lmerTest v. 
3.1.2) using residual maximum likelihood estimates to fit the model and 
maximum likelihood for omnibus analysis of variance (ANOVA). Factors 
included ‘day’ (BL [mean of BS1 and BS2], CS1, CS2, CS3, CS4, CS5, 
RN), ‘group’ (coffee batch ‘162, ‘833’), cognitive ‘workload’ (1-, 2-, 3- 
back) and their interactions as fixed effects, whereas ‘study partici-
pant’ and ‘set size of search items’ (visual search task) were added as 
random effects when appropriate. Distribution of residuals and goodness 
of fit was checked in all models and compared to the results of quantile 
and robust regression methods (R package MASS v.7.3.51.6). In all 
Figures, group means and 95% confidence intervals are presented, based 
on 1000 bootstrap replicates (Efron and Tibshirani, 1993). Post-hoc 
general linear hypothesis tests were computed to compare groups on 
each day of the study, when ‘day’ x ‘group’ interaction terms were sig-
nificant. To correct for multiple comparison, the Benjamini-Hochberg 
procedure was applied (R package multcomp v. 1.4.13). To quantify 
the effect size, Cohen’s d measures were computed for each day of the 
study (Cohen, 1988). 
All results of the linear mixed effects model ANOVAs are summarized 
in Supplementary Tables S1 (self-rated sleepiness and PVT), S2 (visual 
search task), S3 (visuo-spatial and letter n-back tasks), and S4 (caffeine 
and metabolites). The statistical analyses testing differences from 
baseline are illustrated in Supplementary Tables S5-S8. 
3. Results 
The baseline assessments of self-rated sleepiness did not differ be-
tween the two groups. By contrast, cognitive performance was not 
uniformly distributed across all subjects. To avoid overestimating the 
effects of sleep restriction and coffee intake, individual performance 
measures were linearly centered to the mean baseline value of all par-
ticipants (referred to as “normalized to baseline”). Moreover, deviations 
across subjects, were modeled during statistics as random effect. The 
behavioral data were averaged on each study day and the deviations 
from the normalized baseline across the experimental protocol are 
illustrated.  
3.1.1. Subjective sleepiness 
Self-rated sleepiness scores increased after sleep restriction day 2 in 
both groups, irrespectively of whether participants received regular 
coffee or decaffeinated coffee (‘day’: F6,672 = 17.50, p < 0.001) (Sup-
plementary Fig. S2; Supplementary Table S1). Although the mean KSS 
rating was slightly attenuated on sleep restriction day 1 after regular 
coffee administration and appeared to rise less steeply in the regular 
coffee group when compared to the decaffeinated coffee group (‘day’ x 
‘group’ interaction: F6,672 = 3.64, p = 0.001), no significant difference 
between the groups was detected on any day of the experimental pro-
tocol. Interestingly, self-rated sleepiness remained elevated after the 
recovery night in the regular coffee group, but not in the decaffeinated 
coffee group (Fig. S2). 
3.1.2. Psychomotor vigilance test 
Speed, lapses and accuracy on the PVT deteriorated with increasing 
sleep restriction, yet the impairment was attenuated in the regular coffee 
group when compared to the decaffeinated coffee group (‘day’ x ‘group’ 
interactions: speed: F6,672 = 7.72; lapses: F6,672 = 3.69; accuracy: F6,672 
= 4.52; pall < 0.001) (Supplementary Table S1). When compared to 
baseline, the performance impairment in the decaffeinated coffee group 
started between sleep restriction day 1 (speed) and 3 (lapses and accu-
racy) and persisted until the day after the recovery night (Fig. 2). By 
contrast, in the group receiving regular coffee, PVT speed was faster 
than in baseline on sleep restriction days 1 and 2 but fell below baseline 
on sleep restriction days 4 and 5. The slowing in response speed per-
sisted after recovery sleep. A moderate performance impairment oper-
ationalized as an increased number of lapses and reduced accuracy on 
the PVT was evident on sleep restriction day 5. 
The differences between the two groups were not uniform 
throughout the protocol. Mean speed was faster in the regular coffee 
group than in the decaffeinated coffee group on day 1 through 3 of 
chronic sleep restriction, while we observed no differences in PVT speed 
on sleep restriction days 4 and 5. By contrast, on sleep restriction days 3 
and 4, the regular coffee group produced less attentional lapses and 
performed more accurately than the decaffeinated coffee group. More 
specifically, simultaneously correcting for errors of commission and 
errors of omission, accuracy remained stable in both groups on sleep 
restriction days 1 and 2. Afterwards, it steeply decreased with accu-
mulating sleep loss in the decaffeinated coffee group, whereas this 
decrease was delayed and attenuated in the regular coffee group. The 
benefit of regular coffee intake was no longer statistically significant on 
sleep restriction day 5 (Fig. 2; Supplementary Table S5). 
To further characterize the performance differences between the 
groups, the fidelity of information processing in cognition was oper-
ationalized as LSNR, a recently proposed novel measure of PVT perfor-
mance (Chavali et al., 2017). The LSNR was increased in the regular 
coffee group when compared to baseline on sleep restriction days 1 
through 4 and higher than in the decaffeinated coffee group on re-
striction days 1 through 3 (‘day’ x ‘group’ interactions: F6,672 = 9.54, p 
< 0.001; (Supplementary Table S5). Cognitive information processing 
fidelity slightly increased in both groups from baseline to sleep restric-
tion day 1, was highest in the regular coffee group on day 2, and 
decreased in both groups thereafter (‘day’: F6,672 = 7.99, p < 0.001). 
All group differences on the PVT showed large effect sizes (dall >
0.8). No differences in any variable were present following the recovery 
night (Fig. 2). 
3.1.3. Visual search task 
Mean response speed on the visual search task was dependent on the 
set size of visual distractors (not shown) and the presence of the visual 
target. Both, when the target was present and when it was absent, 
response speed remained stable throughout the experiment in the reg-
ular coffee group, while response speed in the decaffeinated coffee 
group was slower than in baseline on virtually all days of sleep restric-
tion and after the recovery night (Fig. 3). The regular coffee group 
performed moderately faster than the decaffeinated coffee group on 
sleep restriction day 5 when the target was present (‘day’ x ‘group’ 
interaction: F6,2759 = 3.08, p = 0.005, ‘group’: F1,26 = 3.28, p = 0.082) 
and on days 4 and 5 of sleep restriction when the target was absent (‘day’ 
x ‘group’ interaction: F6,2759 = 4.83, p < 0.001, ‘group’: F1,26 = 4.29, p 
= 0.049) (Supplementary Tables S2 & S6). Interestingly, the ability to 
correctly recognize the target among the distractors was better than in 
baseline in the regular coffee group on restriction days 3 and 4 and 
impaired in the decaffeinated coffee group on restriction days 2 through 
5. Thus, the regular coffee group performed more accurately throughout 
extended sleep restriction (‘group’: F1,26 = 8.11, p = 0.008; ‘day’ x 
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‘group’ interaction: F6,672 = 4.35, p < 0.001). All group differences were 
of medium to large effect size and no longer present after the recovery 
night. 
3.1.4. Visuo-spatial n-back task 
Response speed and accuracy on the visuo-spatial n-back task 
depended on cognitive workload (speed: F2,2062 = 17.96; accuracy: 
F2,2062 = 465.51; pall < 0.001) and day of the protocol (speed: F6,2062 =
8.16; accuracy: F6,2062 = 16.23; pall < 0.001). Performance speed was 
faster than in baseline on many experimental days in the regular coffee 
group while it fell below the baseline level in the 1-back task on sleep 
restriction days 4 and 5 in the group receiving decaffeinated coffee 
(Fig. 4). Accuracy also deteriorated across sleep restriction on all 
cognitive workloads in the latter group whereas accuracy remained 
virtually unchanged in the former. Thus, the regular coffee group 
performed faster (except on the 3-back task) and/or more accurately 
than the decaffeinated coffee group on the majority of days during sleep 
restriction (‘day’ x ‘group’ interaction: speed: F6,2062 = 9.52; accuracy: 
F6,2062 = 5.13; pall < 0.001) (Supplementary Tables S3 & S7). The dif-
ferences between the groups generally were of medium to large effect 
size and no longer present after the recovery night. 
3.1.5. Letter n-back task 
The visuo-spatial n-back task alike, response speed and accuracy on 
the letter n-back task depended on cognitive workload (speed: F2,2065 =
191.32; accuracy: F2,2065 = 285.36; pall < 0.001) and day of the protocol 
(speed: F6,2065 = 6.43; accuracy: F6,2065 = 9.82; pall < 0.001). The effects 
of sleep restriction and coffee administration were similar to those on 
the visuo-spatial n-back task, except that speed also on the 3-back 
version of the task was enhanced on sleep restriction days 1 through 3 
Fig. 2. Evolution of vigilance across the experimental protocol. On each study day, performance on four psychomotor vigilance test (PVT) sessions spread over the 
entire day were averaged. Lines and shaded areas represent means ±95% confidence intervals in the groups receiving either regular (black; n = 12) or decaffeinated 
coffee (orange; n = 14). Black (regular coffee group) and orange triangles (decaffeinated coffee group) above the x-axis represent Benjamini-Hochberg corrected 
differences (pcorr < 0.05) from baseline (Supplementary Table S5). Stars indicate significant differences between the groups: *p < 0.05. The corresponding effect sizes 
(Cohen’s d) are represented underneath. Dashed blue lines separate regions of “small”, “medium” or “large” effect size. Red dots indicate a significant group dif-
ference (p < 0.05). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
Fig. 3. Evolution of orienting/selection across the experimental protocol. On each study day, performance on four visual search task (VST) sessions spread over the 
entire day were averaged. Lines and shaded areas represent means ±95% confidence intervals in groups receiving either regular (black; n = 12) or decaffeinated 
coffee (orange; n = 14). Accuracy quantified the numbers of correct hits and correct rejections over total responses. Black (regular coffee group) and orange triangles 
(decaffeinated coffee group) above the x-axis represent Benjamini-Hochberg corrected differences (pcorr < 0.05) from baseline (Supplementary Table S6). Stars 
indicate significant differences between the groups: **p < 0.005, *p < 0.05. The corresponding effect sizes (Cohen’s d) are represented underneath. Dashed blue lines 
separate regions of “small”, “medium” or “large” effect size. Red dots indicate a significant group difference (p < 0.05). (For interpretation of the references to colour 
in this figure legend, the reader is referred to the web version of this article.) 
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in the regular coffee group when compared to the decaffeinated coffee 
group (Fig. 5). The evolution of performance differed between the two 
groups (‘day’ x ‘group’ interaction: speed: F6,2065 = 8.11; accuracy: 
F6,2062 = 4.23; pall < 0.001), such that the regular coffee group per-
formed faster and/or more accurately than the decaffeinated coffee 
group on all 3 workload levels on many of sleep restriction days 1 
through 4 (Supplementary Table S8). The differences between the 
groups generally were of large effect size, yet absent on sleep restriction 
day 5 and after the recovery night. 
3.1.6. Caffeine and metabolites 
Confirming that the study participants adhered to the instruction to 
abstain from all sources of caffeine prior to the experiment, caffeine and 
caffeine metabolites were undetectable at bedtime in both groups at 
baseline. Among the group receiving regular coffee, the mean caffeine 
levels increased until sleep restriction day 4, reaching a maximum of 
roughly 6 μmol/l (Fig. 6). Afterwards, the concentration decreased 
because coffee was served only in the morning on sleep restriction day 5 
and no coffee was administered after the recovery night. A similar time 
course, albeit less variable, was seen for the three primary caffeine 
metabolites, paraxanthine, theobromine, and theophylline. Very low 
concentrations of caffeine and metabolites were detected in saliva of the 
control group who received coffee ‘833’, confirming that this batch 
contained only negligible amounts of caffeine (‘day’ x ‘group’ interac-
tion: F6,112 ≥ 10.01, pall < 0.001; Supplementary Table S4). 
4. Discussion 
We addressed the question whether the prevalent habit of drinking 
morning and midday coffee and thus ingesting roughly 300 mg caffeine 
per day ensures optimal attention during chronic sleep restriction. Such 
a coffee intake pattern is common in Europe and South America. We 
found that regular coffee effectively attenuated the repercussions of five 
nights of time-in-bed restricted to 5 h on all three attentional domains 
(vigilance, orienting, executive control) when compared to decaffein-
ated coffee. Our data suggest that ‘real world’ coffee consumption is able 
Fig. 4. Evolution of visuo-spatial working memory and executive control across the experimental protocol. On each study day, performance on four n-back task 
sessions spread over the entire day were averaged. Lines and shaded areas represent means ±95% confidence intervals in groups receiving either regular (black; n =
12) or decaffeinated coffee (orange; n = 14). Normalized mean speed and accuracy, calculated via sum of hits and correct rejections over total responses are shown 
for each step of cognitive load. Black (regular coffee group) and orange triangles (decaffeinated coffee group) above the x-axis represent Benjamini-Hochberg 
corrected differences (pcorr < 0.05) from baseline (Supplementary Table S7). Stars indicate significant differences between the groups: ***p < 0.005, **p < 0.01, 
*p < 0.05. The corresponding effect sizes (Cohen’s d) are represented underneath. Dashed blue lines separate regions of “small”, “medium” or “large” effect size. Red 
dots indicate a significant group difference (p < 0.05). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of 
this article.) 
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to counteract – at least in part - attentional performance impairment in 
genetically caffeine sensitive adults due to repeated sleep restriction, 
which is common in many societies. 
Our findings partly contrast with recent work suggesting that 2 ×
200 mg caffeine per day loses efficacy to counteract the repercussions of 
sleep restriction on vigilance (Doty et al., 2017). In both studies, the 
evolution of subjective sleepiness, PVT speed, and PVT lapses across 
sleep restriction in the groups receiving placebo and decaffeinated cof-
fee was highly similar. In addition, the slowing of mean PVT response 
speed in the active treatment groups was consistently attenuated in both 
experiments during the initial three restriction days. Afterwards, how-
ever, the findings diverged and in the prior report, tolerance to caffeine 
developed. In fact, the number of PVT lapses in the caffeine group was 
even higher than in the placebo group on sleep restriction days 4 and 5 
(Doty et al., 2017). We observed no such tolerance and further perfor-
mance impairment in the present experiment. By contrast, the number of 
lapses in the regular coffee group virtually remained close to the base-
line level up until sleep restriction day 5 when a slight increase was 
observed. Together with more in-depth analyses of accuracy and 
cognitive information processing fidelity underlying PVT performance 
(Chavali et al., 2017), the data confirmed that regular coffee indeed 
provided a benefit over decaffeinated coffee and preserved task per-
formance for 3–4 days of sleep restriction (Fig. 2). 
An important difference between the two studies is the prospective 
genotyping and selective enrolment of participants based on poly-
morphism rs5751875 of ADORA2A in the present experiment. The A2A 
receptor constitutes the primary target structure for caffeine effects on 
vigilance, attention, and sleep-wake regulation (Huang et al., 2005; 
Rétey et al., 2007; Bodenmann et al., 2012; Rupp et al., 2013; Renda 
et al., 2015). According to a new paradigm in the design of human 
studies to test the effects of caffeine and A2A receptor antagonists on 
sleep-wake processes and cognitive functions with decreased variability 
(Holst et al., 2016; Satterfield et al., 2019; Chen and Cunha, 2020), only 
homozygous C-allele carriers of ADORA2A here were examined. Sup-
porting the notion that these individuals are sensitive to the effects of 
caffeine on vigilance and executive control in rested and sleep deprived 
Fig. 5. Evolution of verbal working memory and executive control across the experimental protocol. On each study day, performance on four n-back task sessions 
spread over the entire day were averaged. Lines and shaded areas represent means ±95% confidence intervals in groups receiving either regular (black; n = 12) or 
decaffeinated coffee (orange; n = 14). Normalized mean speed and accuracy, calculated via sum of hits and correct rejections over total responses are shown for each 
step of cognitive load. Black (regular coffee group) and orange triangles (decaffeinated coffee group) above the x-axis represent Benjamini-Hochberg corrected 
differences (pcorr < 0.05) from baseline (Supplementary Table S7). Stars indicate significant differences between the groups: **p < 0.01, *p < 0.05. The corre-
sponding effect sizes (Cohen’s d) are represented underneath. Dashed blue lines separate regions of “small”, “medium” or “large” effect size. Red dots indicate a 
significant group difference (p < 0.05). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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state (Rétey et al., 2007; Renda et al., 2015), clear benefits of coffee on 
objective measures of attentional performance were found. By contrast, 
recent findings suggest that C-allele carriers of this polymorphism 
exhibit reduced interoceptive accuracy when compared to T-allele ho-
mozygotes (Geiger et al., 2016). It may be speculated that the reduced 
processing of interoceptive information in C-allele homozygotes un-
derlies the lack of coffee effects on subjective sleepiness during repeated 
sleep restriction. 
The orienting network may be relatively resilient against the detri-
mental effects of repeated sleep loss (Cunningham et al., 2018). Indeed, 
response speed on the visual search task was only moderately slowed in 
the decaffeinated coffee group and remained unaffected by sleep re-
striction in the regular coffee group. Furthermore, when performance 
accuracy was analyzed, we found a consistent benefit of regular coffee 
over decaffeinated coffee (Fig. 3). This finding adds supporting evidence 
to the notion that caffeine can normalize attention when stressors 
dampen performance and that this benefit can persist for multiple days. 
In accordance with previous findings (Lo et al., 2012), both cognitive 
workload as well as sleep restriction reduced speed and accuracy on 
visuo-spatial and verbal n-back tasks. In general, regular coffee intake 
improved performance with medium to high effect size when compared 
to decaffeinated coffee. Similar to the effect on the alerting network, 
improved response speed on the visuo-spatial n-back task was restricted 
to the initial 3–4 sleep restriction days. Speed on the task with the 
highest cognitive workload (3-back) was the only metric probing exec-
utive control that was not improved by coffee. By contrast, task accuracy 
on all workload levels was boosted by coffee until the final day of sleep 
restriction (Fig. 4). The results on the letter n-back task basically 
corroborated these observations, yet the beneficial effects of coffee only 
lasted to the fourth sleep restriction day (Fig. 5). Together, the findings 
confirm the conclusions of previous work in rested individuals showing 
that caffeine increases executive control functions of the brain (Brunyé 
et al., 2010; Einöther and Giesbrecht, 2013). Functional imaging studies 
showed that caffeine up-regulates prefrontal brain areas in concert with 
anterior cingulate cortex that provide the executive control of visual 
attention (Koppelstaetter et al., 2008). Some evidence in mice suggests 
that caffeine-targeted A2A receptors control information flow in 
prefronto-cortical circuits by synergizing with dopamine D2 receptors 
(Real et al., 2018). Caffeine-induced increased dopaminergic neuro-
transmission in prefrontal cortex may thus support the executive func-
tioning of the brain. 
We intended to investigate the effects of habitual coffee intake which 
in dose and timing is similar to typical human behavior, as a counter-
measure to impaired attention caused by prevailing sleep restriction. To 
standardize the experimental conditions and to avoid withdrawal re-
actions in the decaffeinated group, all study participants abstained from 
caffeine intake for at least 10 days prior to the first sleep restriction day. 
However, in the “real world”, most people consume caffeinated bever-
ages every day, regardless of prior partial sleep loss. Although still a 
matter of discussion, findings in rats and mice indicate that chronic 
caffeine intake increases the number of adenosine receptors and their 
sensitivity both in vitro as well as in vivo, and caffeine withdrawal 
Fig. 6. Evolution of caffeine and caffeine metabolite 
(paraxanthine, theobromine, and theophylline) con-
centrations in saliva at bedtime across the experi-
mental protocol. The last portion of coffee was 
administered in the morning after CS5. The labels BS 
through RN refer to bedtimes of the respective sleep 
episodes, whereas in Figure 2, 3, 4 and 5 the labels 
refer to the wake periods after the respective sleep 
episodes. Lines and shaded areas represent means 
±95% confidence intervals in groups receiving either 
regular (black; n = 10) or decaffeinated coffee (or-
ange; n = 11). Stars indicate significant differences 
between the groups: ***p < 0.005; **p < 0.01, *p <
0.05. (For interpretation of the references to colour in 
this figure legend, the reader is referred to the web 
version of this article.)   
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decreases locomotor activity in rats for several days (reviewed by Nehlig 
et al., 1992). In humans, the regulation of cerebral adenosine receptors 
by chronic caffeine and changes in attentional performance over mul-
tiple days after caffeine abstinence in habitual moderate consumers have 
not been explored. It is intriguing to note that in the present study, 
regular coffee improved several attentional measures, particularly speed 
on the PVT and the n-back tasks, during the first two to three sleep re-
striction days when compared to baseline. This observation could indi-
cate that due to a highly sensitive adenosine system, the re-introduction 
of caffeine not only attenuated the impairment by sleep restriction, but 
initially improved baseline performance despite increasing sleep debt. 
Future research is warranted to study the possible underpinnings of this 
unexpected observation. 
The caffeine and metabolite levels in saliva confirmed that the 
decaffeinated coffee contained negligible amounts of caffeine. The 
concentrations of the caffeine metabolites in the regular coffee group 
reflect the different ratios at which they are formed in the liver 
(Camandola et al., 2019). Among many other phytochemicals, coffee 
contains theobromine and theophylline, whereas paraxanthine is not 
present in plant extracts (Camandola et al., 2019). The psychostimulant 
effects of coffee are commonly attributed to caffeine, which acutely af-
fects neuronal network activity and promotes alertness and attention 
over a wide dose range (McLellan et al., 2016). In humans, caffeine is 
metabolized in the liver through the cytochrome P450 isoenzyme, 
CYP1A2, which accounts for almost all primary metabolism of caffeine. 
The CYP1A2 enzymatic activity exhibits pronounced inter-individual 
variation, likely underlying the large variation in individual saliva 
caffeine concentrations (Fig. 6). Paraxanthine is formed by demethyla-
tion of caffeine. Roughly 10 h after coffee intake, the paraxanthine 
concentration reaches levels comparable to or even higher than those of 
caffeine (Urry et al., 2016; Camandola et al., 2019). The circulating 
concentrations of both these methylxanthines were sufficient to block 
adenosine receptors (Müller and Jacobson, 2011). Both chemicals 
should be considered when interpreting the beneficial effects of coffee 
consumption against the detrimental consequences of repeated sleep 
restriction on vigilance and attention. On the other hand, caffeine easily 
crosses the blood-brain barrier, whereas much less paraxanthine enters 
the brain (Camandola et al., 2019). Because saliva was only sampled at 
bedtime, whereas sleepiness and cognitive performance were tested 
throughout the day, it is not possible to reliably estimate the respective 
contributions of sleep restriction, caffeine, and caffeine metabolites on 
the observed time courses of individual behavioral changes across the 
sleep restriction. Future studies for that purpose are warranted. 
In conclusion, we found that daily 300 mg caffeine intake in coffee 
effectively reduced impairments of vigilance and attention across five 
days/nights of sleep restriction in genetically caffeine sensitive in-
dividuals. The C/C genotype of ADORA2A is present in roughly 35% of 
individuals in European populations. The selective enrolment of this 
genotype thus limits the generalizability of the present results. Never-
theless, the findings support the conclusion that dietary inhibition of 
adenosine A2A receptors can persistently benefit vigilance and attention 
during repeated sleep restriction. The coffee-induced blockade of these 
receptors may potentiate cholinergic and monoaminergic neurotrans-
mission in thalamus, anterior cingulate and other cortical regions that 
regulate vigilance, alerting and executive control (Fan et al., 2005). In 
ongoing analyses of our data that will be published elsewhere, we 
examine whether the repeated coffee consumption also affects the 
consequences of sleep restriction on reversal learning decision making 
(Whitney et al., 2015) and risk taking (Maric et al., 2017). In addition, 
we investigate whether this highly prevalent behavior attenuates or 
accelerates the evolution of waking and sleep electroencephalographic 
markers of sleep need across sleep curtailment and recovery sleep 
(Landolt et al., 2004), as well as possible changes in the availability of 
cerebral adenosine A1 receptors (Elmenhorst et al., 2018). 
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